尤瑞克林治疗轻\中度急性脑梗死的临床疗效观察(3)
 |
| 第1页 |
参见附件(1974KB，3页)。
[2]Duncan J Campbell. The kalllikrein-kinin system in humans [J]. Clinical and Experimental Pharmacology and Physiology,2001,28:1060-1065.
[3]Ann-Maree Duncan. Kinins in humans [J]. Am J Physiol Regulatory Integrative Comp Physiology,2000,278:897-904.
[4]Onesmo Ole-Moiyoi. Structural studies of human urinary kallikrein (urokallikrein) [J]. Proc Natl Acad Sci,1979,76:3121-3125.
[5]Lu HS. Human urinary kallikrein, complete amino acid sequence and sites of glycosylation [J]. Int J Pept Protein Res,1989,33(4):237-49.
[6]Francois Marceau. The B1 Receptors for Kinins [J]. Pharmacological Reviews,1998,50(3):357-386.
[7]Fredrik Leeb-Lundberg. International Union of Pharmacology. XLV, classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences [J]. Pharmacol Rev,2005,57:27-77.
[8]Peter G, Mclean. Kinin B lreceptors and the cardiovascular system: regulation of expression and function[J].Cardiovascular Research,2000,48:194-210.
[9]Simone Wagner. Activation of the tissue kallikrein-kinin system in stroke [J]. Journal of the Neurological Sciences,2002,202:75-76.
[10]Emanueli C, Madeddu P. Angiogenesis therapy with human tissue kallikrein for the treatment of ischemic diseases [J]. Arch Mal Coeur,2004,97:679-87.
[11]Chun-Fang Xia. Kallikrein gene transfer protects against ischemic stroke by promoting glial cell migration and inhibiting apoptosis [J]. Hypertension,2004,43:452-459.
[12]Costanza Emanueli. Prophylactic gene therapy with human tissue kallikrein meliorates limb ischemia recovery in type 1 diabetic mice [J]. Diabetes,2004,53:1096-1103,[13]Bhoola K, Figueroa C, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases [J]. Pharmacol Rev,1992,44:1-80.
[14]中华医学会神经病学分会.各类脑血管疾病诊断要点[J].中华神经科杂志,1996,29(6):379.
[15]中华医学会神经病学分会.脑卒中患者临床神经功能缺损程度评分[J].中华神经科杂志,1996,29(6):381.
(收稿日期：2010-07-29)
您现在查看是摘要介绍页，详见PDF附件(1974KB，3页)。